Agilent Technologies and MRM Proteomics Sign Comarketing Agreement to Further Quantitative Proteomics Solutions

17 Sep 2012
Share
Agilent Technologies Inc. has announced that it has entered into a comarketing agreement with MRM Proteomics Inc., a leading provider of advanced protein quantitation, biomarker and proteomic services to the pharmaceutical, biotechnology and diagnostics industries. The agreement will allow both organizations to offer a more complete solution, including kits, hardware and software for proteomics.

Proteomics is the study of the structure and function of proteins and how they interact within a complex biological system. Agilent’s integrated proteomics workflow provides the highest analytical performance with unprecedented plug-and-play flexibility. Interchangeable workflows simplify setups and let researchers quickly switch between different methodologies. Offering the industry’s highest sensitivity and highest throughput quantitation, the Agilent 6490 Triple Quadrupole MS/MS provides targeted MRM peptide quantitation at attomole detection levels.

“MRM Proteomics, is recognized as a pioneer and leading company in the development of mass spec based methods for protein quantification using multiple reaction monitoring,” said Steve Fischer, Agilent marketing manager, Metabolomics and Proteomics. “The agreement is a further reflection of Agilent’s continued commitment and investment in quantitative proteomics.”

MRM Proteomics specializes in the highly multiplexed absolute quantitation of proteins in complex biological samples such as blood, cerebrospinal fluid and urine through MRM-MS using isotopically labeled internal standards. MRM Proteomics’ workflows utilize minimal sample volumes (20 ul) and are capable of unparalleled specificity and sensitivity, without the need for depletion of high-abundance proteins.

“MRM Proteomics is pleased to enter into this comarketing arrangement with Agilent Technologies; our companies’ offerings are clearly complementary in the field of targeted quantitative proteomics,” said Andrew Munk, chief executive officer of MRM Proteomics. “Mass spectrometry is a rapidly growing platform driving basic proteomics research, biomarker discovery and drug development. Agilent’s status as an innovator in mass spec instrumentation combined with its extensive global network, make Agilent a great partner for MRM Proteomics.”

Request Info


Company website

Agilent Technologies